Eli Lilly and Company (LLY)
Where Will Eli Lilly Be in 1 Year?
Pharmaceutical powerhouse Eli Lilly (LLY 0.37%) had a banner year in 2024. The company's sales surged 32% to over $45 billion on massive growth from its GLP-1 agonist products, Mounjaro for treating type 2 diabetes and Zepbound for chronic weight management.
Lilly sues two compounders over copies of weight-loss drugs
Eli Lilly said on Tuesday it had sued two mass compounders for selling unapproved products that contain tirzepatide, the main ingredient in its popular weight-loss and diabetes medicines.
Eli Lilly (LLY) Rises But Trails Market: What Investors Should Know
In the most recent trading session, Eli Lilly (LLY) closed at $825.91, indicating a +0.41% shift from the previous trading day.
Experimental Lilly drug cuts genetic heart disease risk factor by 94% in trial
The highest dose of an experimental drug developed by Eli Lilly significantly reduced levels of a genetically inherited risk factor for heart disease in a midstage trial, according to data presented at a major medical meeting on Sunday.
1 Growth Stock With Major Catalysts on the Way to Buy and Hold
After starting 2024 strong, Eli Lilly (LLY -0.16%) did not perform well in the second half of last year. Its financial results, though solid compared to similarly sized peers, were not always up to investors' high standards for the market-leading drugmaker.
2 healthcare stocks to buy ahead of Trump's pharmaceutical tariffs
United States President Donald Trump has hinted that the pharmaceutical sector will likely be the next to be hit with tariffs. While announcing on March 28, Trump did not specify the date or rates involved, but the decision will likely trigger more market uncertainty.
2 healthcare safe bets to buy ahead of Trump's pharmaceutical tariffs
United States President Donald Trump has hinted that the pharmaceutical sector will likely be the next to be hit with tariffs. While announcing on March 28, Trump did not specify the date or rates involved, but the decision will likely trigger more market uncertainty.
CHMP Recommends Against Approval of Eli Lilly's Kisunla Alzheimer's Drug -- Update
A key European regulatory committee has recommended against approval of Eli Lilly's Kisunla, saying the benefits of the Alzheimer's disease drug don't outweigh its risks.
Eli Lilly and Company (LLY) Is a Trending Stock: Facts to Know Before Betting on It
Zacks.com users have recently been watching Lilly (LLY) quite a bit. Thus, it is worth knowing the facts that could determine the stock's prospects.
EU medicines regulator rejects Eli Lilly's Alzheimer's drug
The European Union's drugs regulator on Friday rejected Eli Lilly's Alzheimer's drug Kisunla, saying the risk of serious brain swelling did not outweigh the treatment's small impact on slowing cognitive decline.
Lilly adds Alzheimer's to online offerings
Eli Lilly on Thursday expanded its direct-to-consumer online platform LillyDirect to include telehealth providers to diagnose and care for patients with Alzheimer's disease, potentially boosting sales of its drug Kisunla.
Eli Lilly, Palo Alto Networks Traders Take Note: Direxion's New Leveraged ETFs Are Here
Active traders have new, highly powered tools at their disposal as Direxion rolls out four single-stock leveraged and inverse exchange-traded funds.
